Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : TaiRx
Deal Size : Undisclosed
Deal Type : Partnership
Bora Pharmaceuticals Partners with TaiRx
Details : CVM-1118 (foslinanib) is a new small molecule chemical entity and a potential anti-cancer agent in numerous human cancer cell lines with strong anti-cancer activity, high safety margin, and multiple mechanisms of actions in targeting cancer-specific fact...
Product Name : CVM-1118
Product Type : Small molecule
Upfront Cash : Undisclosed
September 27, 2022
Lead Product(s) : Foslinanib,Sorafenib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : TaiRx
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : VDA-1275,Sorafenib,Cisplatin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Vidac Presents High Efficacy Data For Next-Generation Cancer Drug Candidate In Solid Tumor
Details : VDA-1275 is a potent small molecule new chemical entity (NCE) with novel mechanism of action that selectively modulates VDAC/HK2 interaction. It is being developed for the treatment of solid tumors.
Product Name : VDA-1275
Product Type : Small molecule
Upfront Cash : Not Applicable
February 19, 2024
Lead Product(s) : VDA-1275,Sorafenib,Cisplatin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OUTREACH-2 study evaluating MTL-CEBPA specifically up-regulates CCAAT/enhancer-binding protein alpha (C/EBP-α) in combination with sorafenib, in comparison to sorafenib alone, in up to 150 patients.
Product Name : MTL-CEBPA
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
January 25, 2022
Details : The median sorafenib treatment duration was only nine weeks, a much shorter treatment duration than the referenced historical controls. The median treatment duration of TTFields was 10 weeks.
Product Name : Nexavar
Product Type : Small molecule
Upfront Cash : Not Applicable
July 01, 2021
Details : Last patient has been enrolled in the HEPANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields in combination with sorafenib in patients with advanced liver cancer.
Product Name : Nexavar
Product Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2020
Details : Observed clinical activity, including durable and complete tumour responses, suggests that MTL-CEBPA may increase the effectiveness of sorafenib standard of care.
Product Name : MTL-CEBPA
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
May 29, 2020
Details : The randomized, placebo-controlled Phase 2b study of YIV-906 is evaluating efficacy, safety, and quality of life in patients with hepatitis B-positive HCC.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Not Applicable
April 06, 2020
Reset All
Bora Pharmaceuticals- Making success more certain.
